Literature DB >> 1349129

Cyclosporin leukoencephalopathy induced by intravenous lipid solution.

N De Klippel, J Sennesael, J Lamote, G Ebinger, J de Keyser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349129     DOI： 10.1016/0140-6736(92)90707-a

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.

Authors:  Kishor M Wasan; Manisha Ramaswamy; Mona Kwong; Kathy D Boulanger
Journal:  AAPS PharmSci       Date:  2002

2.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

3.  Acute serum lipid changes in a renal transplant recipient on intravenous cyclosporin upon administration of an intravenous lipid solution.

Authors:  J Bolodeoku; G J Mellotte
Journal:  Postgrad Med J       Date:  1994-11       Impact factor: 2.401

4.  Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Authors:  K M Wasan; P H Pritchard; M Ramaswamy; W Wong; E M Donnachie; L J Brunner
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

5.  Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins.

Authors:  Kishor M Wasan; Olena Sivak
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

6.  Cyclosporine binds to the neutral lipid and potentially other binding sites of lipid transfer protein I.

Authors:  Mona Kwong; Kishor M Wasan
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 7.  Acute leucoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome.

Authors:  C Shimizu; S Kimura; Y Yoshida; A Nezu; K Saitoh; H Osaka; Y Aihara; Y Nagasaka
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

8.  Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics.

Authors:  A Fahr; M Holz; G Fricker
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

9.  Gemcitabine monotherapy associated with posterior reversible encephalopathy syndrome.

Authors:  Luiz Carlos Porcello Marrone; Bianca Fontana Marrone; Julia de la Puerta Raya; Giovani Gadonski; Jaderson Costa da Costa
Journal:  Case Rep Oncol       Date:  2011-02-16

10.  Posterior reversible encephalopathy syndrome could be an underestimated variant of "reversible neurological deficits" in Systemic Lupus Erythematosus.

Authors:  Bin Liu; Xuan Zhang; Feng-Chun Zhang; Yuan Yao; Ri-Zhi Zhou; Miao-Miao Xin; Li-Qin Wang
Journal:  BMC Neurol       Date:  2012-12-05       Impact factor: 2.474
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.